Carbapenemase-producing Gram-negative bacteria: Current epidemics, antimicrobial susceptibility and treatment options

Future Microbiology

Volumn 10, Issue 3, 2015, Pages 407-425

  Jean, Shio Shin ^a   Lee, Wen Sen ^a   Lam, Carlos ^a   Hsu, Chin Wang ^a   Chen, Ray Jade ^a   Hsueh, Po Ren ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Carbapenemase; Combination therapy; Dissemination; Gram negative bacteria; Resistance

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BACTERIAL ENZYME; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; CEPHALOSPORIN; CLAVULANIC ACID; CLOXACILLIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; HYDROLASE; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; MEROPENEM; METALLO BETA LACTAMASE; MICROBIAL ENZYME; NDM ENZYME; OXACILLIN; OXACILLINASE; QUINOLONE DERIVATIVE; SERRATIA MARCESCENS ENZYME; SULBACTAM; TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIM PROTEIN; ANTIINFECTIVE AGENT; BETA-LACTAMASE NDM-1;

ACINETOBACTER; ACINETOBACTER BAUMANNII; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; ENTEROBACTERIACEAE; EPIDEMIC; FATALITY; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INTEGRON; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GRAM-NEGATIVE BACTERIAL INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

KLEBSIELLA PNEUMONIAE; NEGIBACTERIA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84926153992     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/FMB.14.135     Document Type: Review

References (196)

1. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20(3), 440-458 (2007).
2. Ambler RP. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 289, 321-331 (1980).
3. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9(4), 228-236 (2009).
4. VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J. Antimicrob. Chemother. 61(1), 59-63 (2008).
5. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J. Clin. Microbiol. 43(9), 4826-4829 (2005).
6. OXA-23 in Acinetobacter baumannii. Antimicrob. Agents Chemother. 51(4), 1530-1533 (2007).
7. Turton JF, Ward ME, Woodford N et al. The role of IS Aba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 258(1), 72-77 (2006).
8. Carrër A, Poirel L, Yilmaz M et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob. Agents Chemother. 54(3), 1369-1373 (2010).
9. Jean SS, Lee WS, Hsueh PR. Nationwide spread of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan. J. Microbiol. Immunol. Infect. 46(5), 317-319 (2013).
10. Toleman MA, Biedenbach D, Bennett DM, Jones RN, Walsh TR. Italian metallo-β-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. J. Antimicrob. Chemother. 55(1), 61-70 (2005).
11. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597-602 (2010).
12. OXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg. Infect. Dis. 16(1), 35-40 (2010).
13. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J. Antimicrob. Chemother. 63(1), 55-59 (2009).
14. Lee YT, Fung CP, Wang FD, Chen CP, Chen TL, Cho WL. Outbreak of imipenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex harboring different carbapenemase gene-associated genetic structures in an intensive care unit. J. Microbiol. Immunol. Infect. 45(1), 43-51 (2012).
15. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17(10), 1791-1798 (2011).
16. Perez F, Endimiani A, Ray AJ et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J. Antimicrob. Chemother. 65(8), 1807-1818 (2010).
17. Bratu S, Landman D, Haag R et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165(12), 1430-1435 (2005).
18. Navon-Venezia S, Leavitt A, Schwaber MJ et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob. Agents Chemother. 53(2), 818-820 (2009).
19. Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J. Antimicrob. Chemother. 66(2), 307-312 (2011).
20. Woodford N, Tierno PM Jr, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. 48(12), 4793-4799 (2004).
21. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the β-lactamase bla KPC gene. Antimicrob. Agents Chemother. 52(4), 1257-1263 (2008).
22. KPC-2 gene. Emerg. Infect. Dis. 16(9), 1349-1356 (2010).
23. Chen YT, Lin JC, Fung CP et al. KPC-2-encoding plasmids from Escherichia coli and Klebsiella pneumoniae in Taiwan. J. Antimicrob. Chemother. 69(3), 628-631 (2014).
24. KPC-harboring IncFIA plasmids in New Jersey and New York hospitals. Antimicrob. Agents Chemother. 58(4), 2289-2294 (2014).
25. Ke W, Bethel CR, Thomson JM, Bonomo RA, van den Akker F. Crystal structure of KPC-2: insights into carbapenemase activity in class A β-lactamases. Biochemistry 46(19), 5732-5740 (2007).
26. Chiu SK, Wu TL, Chuang YC et al. National surveillance study on carbapenem nonsusceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS ONE 8(7), e69428 (2013).
27. Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob. Agents Chemother. 52(6), 2014-2018 (2008).
28. KPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J. Antimicrob. Chemother. 63(3), 427-437 (2009).
29. KPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J. Antimicrob. Chemother. 66(7), 1510-1513 (2011).
30. Endimiani A, Carias LL, Hujer AM et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing bla KPC in the United States. Antimicrob. Agents Chemother. 52(7), 2680-2682 (2008).
31. Li JJ, Sheng ZK, Deng M et al. Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese University Hospital. BMC Infect. Dis. 12, 373-380 (2012).
32. Landman D, Bratu S, Quale J. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J. Med. Microbiol. 58(Pt 10), 1303-1308 (2009).
33. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob. Agents Chemother. 51(4), 1553-1555 (2007).
34. Robledo IE, Aquino EE, Santé MI et al. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob. Agents Chemother. 54(3), 1354-1357 (2010).
35. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45(4), 1151-1161 (2001).
36. Yang YJ, Wu PJ, Livermore DM. Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob. Agents Chemother. 34(5), 755-758 (1990).
37. Nordmann P, Mariotte S, Naas T, Labia R, Nicolas MH. Biochemical properties of a carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrob. Agents Chemother. 37(54), 939-946 (1993).
38. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47(4), 1297-1300 (2003).
39. Johnson JK, Wilson LE, Zhao L, Richards K, Thom KA, Harris AD. Point prevalence of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae in Maryland. Infect. Control Hosp. Epidemiol. 35(4), 443-445 (2014).
40. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob. Agents Chemother. 50(9), 3098-3101 (2006).
41. Yoo JS, Kim HM, Yoo JI et al. Detection of clonal KPC-2-producing Klebsiella pneumoniae ST258 in Korea during nationwide surveillance in 2011. J. Med. Microbiol. 62(Pt 9), 1338-1342 (2013).
42. Jean SS, Hsueh PR. Spread of Klebsiella pneumoniae carbapenemase-2-producing Klebsiella pneumoniae clones in Asia. Future Microbiol. 9(3), 273-275 (2014).
43. Baraniak A, Izdebski R, Herda M et al. Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. Antimicrob. Agents Chemother. 53(10), 4565-4567 (2009).
44. Carbonne A, Thiolet JM, Fournier S et al. Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. Euro. Surveill. 15(48), pii: 19734 (2010).
45. KPC-2-producing Klebsiella pneumoniae in Singapore. J. Clin. Microbiol. 50(2), 475-476 (2012).
46. Giani T, Pini B, Arena F et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro. Surveill. 18(22), pii: 20489 (2013).
47. Giani T, D'Andrea MM, Pecile P et al. Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 Carbapenemase. J. Clin. Microbiol. 47(11), 3793-3794 (2009).
48. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med. Mal. Infect. 44(2), 51-56 (2014).
49. Cantón R, Akóva M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18(5), 413-431 (2012).
50. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broadspectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamaseproducing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 52(2), 570-573 (2008).
51. Prabaker K, Lin MY, McNally M et al. Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: a multihospital study. Infect. Control Hosp. Epidemiol. 33(12), 1193-1199 (2012).
52. Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Rev. Anti. Infect. Ther. 12(5), 565-580 (2014).
53. Rasmussen BA, Bush K, Keeney D et al. Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob. Agents Chemother. 40(9), 2080-2086 (1996).
54. Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A β-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob. Agents Chemother. 38(6), 1262-1270 (1994).
55. Naas T, Nordmann P. Analysis of a carbapenem-hydrolyzing class A β-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. Proc. Natl. Acad. Sci. USA 91(16), 7693-7697 (1994).
56. Troillet N, Carmeli Y, Venkataraman L, DeGirolami P, Samore MH. Epidemiological analysis of imipenem-resistant Serratia marcescens in hospitalized patients. J. Hosp. Infect. 42(1), 37-43 (1999).
57. Pottumarthy S, Moland ES, Juretschko S, Swanzy SR, Thomson KS, Fritsche TR. NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg. Infect. Dis. 9(8), 999-1002 (2003).
58. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 45(9), 2598-2603 (2001).
59. Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J. Antimicrob. Chemother. 49(3), 561-565 (2002).
60. Wachino J, Doi Y, Yamane K et al. Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a β-lactamase, GES-3, in a neonatal intensive care unit in Japan. Antimicrob. Agents Chemother. 48(6), 1960-1967 (2004).
61. VIM family in a GES-1 extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa clinical isolate in Argentina. Antimicrob. Agents Chemother. 49(1), 474-475 (2005).
62. Duarte A, Boavida F, Grosso F et al. Outbreak of GES-1 β-lactamase-producing multidrug-resistant Klebsiella pneumoniae in a university hospital in Lisbon, Portugal. Antimicrob. Agents Chemother. 47(4), 1481-1482 (2003).
63. Lim HM, Pène JJ, Shaw RW. Cloning, nucleotide sequence, and expression of the Bacillus cereus 5/B/6 β-lactamase II structural gene. J. Bacteriol. 170(6), 2873-2878 (1988).
64. Iaconis JP, Sanders CC. Purification and characterization of inducible β-lactamases in Aeromonas spp. Antimicrob. Agents Chemother. 34(1), 44-51 (1990).
65. Saino Y, Kobayashi F, Inoue M, Mitsuhashi S. Purification and properties of inducible penicillin β-lactamase isolated from Pseudomonas maltophilia. Antimicrob. Agents Chemother. 22(4), 564-570 (1982).
66. Nishio H, Komatsu M, Shibata N et al. Metallo-β-lactamase-producing gramnegative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J. Clin. Microbiol. 42(11), 5256-5263 (2004).
67. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 35(1), 147-151 (1991).
68. IMP among clinically isolated strains of Serratia marcescens. Antimicrob. Agents Chemother. 39(4), 824-829 (1995).
69. IMP allelic variants carried by gene cassettes of different phylogeny. Antimicrob. Agents Chemother. 44(5), 1229-1235 (2000).
70. IMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin. Infect. Dis. 41(11), 1549-1556 (2005).
71. Hanson ND, Hossain A, Buck L, Moland ES, Thomson KS. First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-β-lactamase, IMP-18. Antimicrob. Agents Chemother. 50(6), 2272-2273 (2006).
72. Lincopan N, McCulloch JA, Reinert C, Cassettari VC, Gales AC, Mamizuka EM. First isolation of metallo-β-lactamaseproducing multiresistant Klebsiella pneumoniae from a patient in Brazil. J. Clin. Microbiol. 43(1), 516-519 (2005).
73. Hung KH, Yan JJ, Lu JJ, Chen HM, Wu JJ. Characterization of the modified Hodge test-positive isolates of Enterobacteriaceae in Taiwan. J. Microbiol. Immunol. Infect. 46(1), 35-40 (2013).
74. Koyano S, Saito R, Nagai R et al. Molecular characterization of carbapenemase-producing clinical isolates of Enterobacteriaceae in a teaching hospital, Japan. J. Med. Microbiol. 62(Pt 3), 446-450 (2013).
75. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18(2), 306-325 (2005).
76. Koratzanis E, Souli M, Galani I, Chryssouli Z, Armaganidis A, Giamarellou H. Epidemiology and molecular characterisation of metallo-β-lactamase-producing Enterobacteriaceae in a university hospital Intensive Care Unit in Greece. Int. J. Antimicrob. Agents 38(5), 390-397 (2011).
77. Steinmann J, Kaase M, Gatermann S et al. Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro. Surveill. 16(33), pii: 19944 (2011).
78. Vatopoulos A. High rates of metallo-β-lactamase-producing Klebsiella pneumoniae in Greece - a review of the current evidence. Euro. Surveill. 13(4), 8023 (2008).
79. Poirel L, Naas T, Nicolas D et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44(4), 891-897 (2000).
80. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43(7), 1584-1590 (1999).
81. Marcano D, Pasterán F, Rapoport M et al. First isolation of a VIM-producing Klebsiella pneumoniae from a seven-year-old child in Venezuela. J. Infect. Dev. Ctries. 2(3), 241-244 (2008).
82. Ktari S, Arlet G, Mnif B et al. Emergence of multidrug-resistant Klebsiella pneumoniae isolates producing VIM-4 metallo-β-lactamase, CTX-M-15 extended-spectrum β-lactamase, and CMY-4 AmpC β-lactamase in a Tunisian university hospital. Antimicrob. Agents Chemother. 50(12), 4198-4201 (2006).
83. Wang C, Wang J, Mi Z. Pseudomonas aeruginosa producing VIM-2 metallo-β-lactamases and carrying two aminoglycosidemodifying enzymes in China. J. Hosp. Infect. 62(4), 522-524 (2006).
84. VIM-7, an evolutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 48(1), 329-332 (2004).
85. Grundmann H, Livermore DM, Giske CG et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro. Surveill. 15(46), pii: 19711 (2010).
86. Glasner C, Albiger B, Buist G et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro. Surveill. 18(28), pii: 20525 (2013).
87. Huang YT, Chang SC, Lauderdale TL, Yang AJ, Wang JT. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa carrying metallo-β-lactamase genes in Taiwan. Diagn. Microbiol. Infect. Dis. 59(2), 211-216 (2007).
88. Lin KY, Lauderdale TL, Wang JT, Chang SC. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections. J. Microbiol. Immunol. Infect. doi: 10.1016/j.jmii.2014.01.005 (2014) (Epub ahead of print).
89. Fournier D, Richardot C, Müller E et al. Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 68(8), 1772-1780 (2013).
90. VIM-1 J. Antimicrob. Chemother. 58(3), 669-672 (2006).
91. Sánchez-Romero I, Asensio A, Oteo J et al. Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome. Antimicrob. Agents Chemother. 56(1), 420-427 (2012).
92. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34(5), 634-640 (2002).
93. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47(5), 1681-1688 (2003).
94. Tsakris A, Pournaras S, Woodford N et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J. Clin. Microbiol. 38(3), 1290-1292 (2000).
95. Jones RN, Deshpande LM, Bell JM et al. Evaluation of the contemporary occurrence rates of metallo-β-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Diagn. Microbiol. Infect. Dis. 49(4), 289-294 (2004).
96. IMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. J. Antimicrob. Chemother. 52(4), 583-590 (2003).
97. Van der Bij AK, Van Mansfeld R, Peirano G et al. First outbreak of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes. Int. J. Antimicrob. Agents 37(6), 513-518 (2011).
98. Zowawi HM, Balkhy HH, Walsh TR, Paterson DL. β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin. Microbiol. Rev. 26(3), 361-380 (2013).
99. Daikos GL, Karabinis A, Paramythiotou E et al. VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int. J. Antimicrob. Agents 29(4), 471-473 (2007).
100. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53(5), 1868-1873 (2009).
101. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).
102. Liu Z, Li W, Wang J et al. Identification and characterization of the first Escherichia coli strain carrying NDM-1 gene in China. PLoS One 8(6), e66666 (2013).
103. Blyth CC, Pereira L, Goire N. New Delhi metallo-β-lactamase-producing enterobacteriaceae in an Australian child who had not travelled overseas. Med. J. Aust. 200(7), 386 (2014).
104. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11(5), 355-362 (2011).
105. Bonomo RA. New Delhi metallo-β-lactamase and multidrug resistance: a global SOS? Clin. Infect. Dis. 52(4), 485-487 (2011).
106. Ho PL, Lo WU, Yeung MK et al. Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLoS One 6(3), e17989 (2011).
107. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-β-lactamase NDM-1-producing multidrugresistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 54(11), 4914-4916 (2010).
108. Miriagou V, Carattoli A, Tzelepi E, Villa L, Tzouvelekis LS. IS26-associated In4-type integrons forming multiresistance loci in enterobacterial plasmids. Antimicrob. Agents Chemother. 49(8), 3541-3543 (2005).
109. Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother. 66(4), 689-692 (2011).
110. Shanthi M, Sekar U, Sowmiya M et al. Clonal diversity of New Delhi metallo-β-lactamase-1 producing Enterobacteriaceae in a tertiary care centre. Indian J. Med. Microbiol. 31(3), 237-241 (2013).
111. Rolain JM, Parola P, Cornaglia G. New Delhi metallo-β-lactamase (NDM-1): towards a new pandemia? Clin. Microbiol. Infect. 16(12), 1699-1701 (2010).
112. Jovcic B, Lepsanovic Z, Suljagic V et al. Emergence of NDM-1 metallo-β-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob. Agents Chemother. 55(8), 3929-3931 (2011).
113. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55(1), 390-394 (2011).
114. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect. doi: 10.1111/1469-0691.12697 (Epub ahead of print) (2014).
115. Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B et al. Outbreak of NDM-1-producing Klebsiella pneumoniae in a neonatal unit in Colombia. Antimicrob. Agents Chemother. 57(4), 1957-1960 (2013).
116. Pasteran F, Albornoz E, Faccone D et al. Emergence of NDM-1-producing Klebsiella pneumoniae in Guatemala. J. Antimicrob. Chemother. 67(7), 1795-1797 (2012).
117. Rogers BA, Sidjabat HE, Silvey A et al. Treatment options for New Delhi metallo-β-lactamase-harboring enterobacteriaceae. Microb. Drug Resist. 19(2), 100-103 (2013).
118. Sidjabat H, Nimmo GR, Walsh TR et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase. Clin. Infect. Dis. 52(4), 481-484 (2011).
119. Dash N, Panigrahi D, Al Zarouni M et al. High Incidence of New Delhi Metallo-β-Lactamase producing Klebsiella pneumoniae Isolates in Sharjah, United Arab Emirates. Microb. Drug Resist. 20(1), 52-56 (2014).
120. Livermore DM, Walsh TR, Toleman M, Woodford N. Balkan NDM-1: escape or transplant? Lancet Infect. Dis. 11(3), 164 (2011).
121. Nordmann P, Couard JP, Sansot D, Poirel L. Emergence of an autochthonous and community-acquired NDM-1-producing Klebsiella pneumoniae in Europe. Clin. Infect. Dis. 54(1), 150-151 (2012).
122. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25(4), 682-707 (2012).
123. SPM-1-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob. Agents Chemother. 48(4), 1406-1409 (2004).
124. Zavascki AP, Gaspareto PB, Martins AF, Gonçalves AL, Barth AL. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-β-lactamase in a teaching hospital in southern Brazil. J. Antimicrob. Chemother. 56(6), 1148-1151 (2005).
125. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a β-lactamase gene, bla GIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob. Agents Chemother. 48(12), 4654-4661 (2004).
126. Rieber H, Frontzek A, Pfeifer Y. Emergence of metallo-β-lactamase GIM-1 in a clinical isolate of Serratia marcescens. Antimicrob. Agents Chemother. 56(9), 4945-4947 (2012).
127. Hamprecht A, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P. Detection of the carbapenemase GIM-1 in Enterobacter cloacae in Germany. J. Antimicrob. Chemother. 68(3), 558-561 (2013).
128. SIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother. 49(11), 4485-4491 (2005).
129. Huang ST, Chiang MC, Kuo SC et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J. Microbiol. Immunol. Infect. 45(5), 356-362 (2012).
130. Hujer KM, Hujer AM, Hulten EA et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 50(12), 4114-4123 (2006).
131. Bush K. Recent developments in β-lactamase research and their implications for the future. Rev. Infect. Dis. 10(4), 681-690 (1988).
132. Paton R, Miles RS, Hood J, Amyes SG, Miles RS, Amyes SG. ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int. J. Antimicrob. Agents 2(2), 81-87 (1993).
133. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA β-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob. Agents Chemother. 44(1), 196-199 (2000).
134. OXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int. J. Antimicrob. Agents 34(1), 25-28 (2009).
135. Turton JF, Kaufmann ME, Glover J et al. Detection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United Kingdom. J. Clin. Microbiol. 43(7), 3074-3082 (2005).
136. Da Silva GJ, Quinteira S, Bértolo E et al. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J. Antimicrob. Chemother. 54(1), 255-258 (2004).
137. Ku WW, Kung CH, Lee CH et al. Evolution of carbapenem resistance in Acinetobacter baumannii: An 18-year longitudinal study from a medical center in northern Taiwan. J. Microbiol. Immunol. Infect. doi:: 10.1016/j.jmii.2013.07.005 (2013) (Epub ahead of print).
138. Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49(8), 3198-3202 (2005).
139. Bou G, Cerveró G, Domínguez MA, Quereda C, Martínez-Beltrán J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J. Clin. Microbiol. 38(9), 3299-3305 (2000).
140. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J. Antimicrob. Chemother. 52(4), 629-635 (2003).
141. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(1), 15-22 (2004).
142. Ledent P, Raquet X, Joris B, Van Beeumen J, Frère JM. A comparative study of class-D β-lactamases. Biochem. J. 292(Pt 2), 555-562 (1993).
143. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 45(2), 583-588 (2001).
144. Maveyraud L, Golemi-Kotra D, Ishiwata A, Meroueh O, Mobashery S, Samama JP. High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 β-lactamase. J. Am. Chem. Soc. 124(11), 2461-2465 (2002).
145. Poirel L, Marqué S, Héritier C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49(1), 202-208 (2005).
146. Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Chemother. 44(6), 1556-1561 (2000).
147. Chuang YC, Sheng WH, Lauderdale TL et al. Molecular epidemiology, antimicrobial susceptibility and carbapenemase resistance determinants among Acinetobacter baumannii clinical isolates in Taiwan. J. Microbiol. Immunol. Infect. doi: 10.1016/j.jmii.2013.03.008 (2013) (Epub ahead of print).
148. Poirel L, Nordmann P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene bla OXA-58 in Acinetobacter baumannii. Antimicrob. Agents Chemother. 50(4), 1442-1448 (2006).
149. OXA-58 gene with its hybrid promoter provided by IS1006 and an IS Aba3-like element to β-lactam resistance in Acinetobacter genomic species 13TU. Antimicrob. Agents Chemother. 54(8), 3107-3112 (2010).
150. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 12(9), 826-836 (2006).
151. Jeon BC, Jeong SH, Bae IK et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 β-lactamase in Korea. J. Clin. Microbiol. 43(5), 2241-2245 (2005).
152. Stoeva T, Higgins PG, Bojkova K, Seifert H. Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital. Clin. Microbiol. Infect. 14(7), 723-727 (2008).
153. Mesli E, Berrazeg M, Drissi M, Bekkhoucha SN, Rolain JM. Prevalence of carbapenemase-encoding genes including New Delhi metallo-β-lactamase in Acinetobacter species, Algeria. Int. J. Infect. Dis. 17(9), e739 (2013).
154. OXA-23 from hospitals in central Taiwan. J. Microbiol. Immunol. Infect. 46(6), 419-424 (2013).
155. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J. Infect. Dev. Ctries. 3(5), 335-341 (2009).
156. Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob. Agents Chemother. 50(2), 756-758 (2006).
157. Marqué S, Poirel L, Héritier C et al. Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J. Clin. Microbiol. 43(9), 4885-4888 (2005).
158. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob. Agents Chemother. 50(9), 2941-2945 (2006).
159. Poirel L, Héritier C, Nordmann P. Chromosome-encoded Ambler class D β-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. Antimicrob. Agents Chemother. 48(1), 348-351 (2004).
160. Walther-Rasmussen J, HØiby N. OXA-type carbapenemases. J. Antimicrob. Chemother. 57(3), 373-383 (2006).
161. Moquet O, Bouchiat C, Kinana A et al. Class D OXA-48 carbapenemase in multidrugresistant enterobacteria, Senegal. Emerg. Infect. Dis. 17(1), 143-144 (2011).
162. Cuzon G, Naas T, Lesenne A, Benhamou M, Nordmann P. Plasmid-mediated carbapenem-hydrolysing OXA-48 β-lactamase in Klebsiella pneumoniae from Tunisia. Int. J. Antimicrob. Agents 36(1), 91-93 (2010).
163. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob. Agents Chemother. 55(3), 1274-1278 (2011).
164. Oteo J, Saez D, Bautista V et al. Carbapenemase-producing Enterobacteriaceae in Spain in 2012. Antimicrob. Agents Chemother. 57(12), 6344-6347 (2013).
165. Poirel L, Castanheira M, Carrër A et al. OXA-163, an OXA-48-related class D β-lactamase with extended activity toward expanded-spectrum cephalosporins. Antimicrob. Agents Chemother. 55(6), 2546-2551 (2011).
166. Voulgari E, Zarkotou O, Ranellou K et al. Outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in Greece involving an ST11 clone. J. Antimicrob. Chemother. 68(1), 84-88 (2013).
167. Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 41(6), 582-585 (2013).
168. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(6), 3002-3004 (2011).
169. Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56(1), 128-132 (2005).
170. Kontopoulou K, Protonotariou E, Vasilakos K et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin. J. Hosp. Infect. 76(1), 70-73 (2010).
171. Spanu T, De Angelis G, Cipriani M et al. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 56(8), 4516-4518 (2012).
172. Samonis G, Matthaiou DK, Kofteridis D, Maraki S, Falagas ME. In vitro susceptibility to various antibiotics of colistin-resistant Gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin. Infect. Dis. 50(12), 1689-1691 (2010).
173. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55(7), 3284-3294 (2011).
174. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J. Antimicrob. Chemother. 66(9), 1963-1971 (2011).
175. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob. Agents Chemother. 58(2), 654-663 (2014).
176. KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54(1), 526-529 (2010).
177. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 16(2), 184-186 (2010).
178. Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 56(6), 3395-3398 (2012).
179. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47(5), 1611-1612 (2009).
180. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56(4), 2108-2113 (2012).
181. Clinical and Laboratory Standards Institute. Performance Standards For Antimicrobial Susceptibility Testing; Twenty-first Informational Supplement. CLSI document M100-S21. CLSI, PA, USA (2011).
182. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev. Anti. Infect. Ther. 10(12), 1393-1404 (2012).
183. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann. Clin. Microbiol. Antimicrob. 11, 32 (2012).
184. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55(7), 943-950 (2012).
185. Daikos GL, Tsaousi S, Tzouvelekis LS et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob. Agents Chemother. 58(4), 2322-2328 (2014).
186. European Committee on Antimicrobial Susceptibility Testing. Breakpoints tables for interpretation of MICs and zone diameters, version 3.1 (2013).
187. Jean SS, Hsueh PR. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert. Opin. Pharmacother. 12(14), 2145-2148 (2011).
188. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43(10), 1116-1123 (2003).
189. Bonnefoy A, Dupuis-Hamelin C, Steier V et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54(2), 410-417 (2004).
190. Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 9, 13-25 (2014).
191. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(1), 82-85 (2011).
192. Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 68(10), 2286-2290 (2013).
193. Lee NY, Lee JC, Li MC, Li CW, Ko WC. Empirical antimicrobial therapy for critically ill patients with Acinetobacter baumannii bacteremia: Combination is better. J. Microbiol. Immunol. Infect. 46(5), 397-398 (2013).
194. Shields RK, Clancy CJ, Gillis LM et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS ONE 7(12), e52349 (2012).
195. Durante-Mangoni E, Signoriello G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin. Infect. Dis. 57(3), 349-358 (2013).
196. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34(1), 8. e1-8.e9 (2009).